GlassScriptPhysician profile
Tommy Wayne Wagner
NPI 1952385064
$1,454.92
in general payments reported to CMS, 2019-2025
20 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.10 · 2020: $123 · 2021: $197 · 2022: $160 · 2023: $162 · 2024: $436 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $253.55 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $221.75 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $217.01 | 2021-2025 | |
| Lilly USA, LLC | $111.34 | 2020-2022 | |
| Novo Nordisk INC | $106.24 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $77.86 | 2024-2025 | Auvelity |
| Exact Sciences Corporation | $57.52 | 2023-2024 | Cologuard Collection Kit |
| Insulet Corporation | $51.28 | 2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.81 | 2022-2024 | Xifaxan |
| Amgen INC. | $46.99 | 2020-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.43 | 2019-2025 | Jardiance |
| Supernus Pharmaceuticals, INC. | $33.40 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $32.52 | 2022-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.39 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $29.27 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $25.24 | 2024 | Gemtesa |
| Tris Pharma INC | $20.70 | 2024 | Dyanavel Xr |
| Verona Pharma, INC. | $20.56 | 2025 | Ohtuvayre |
| Pfizer INC. | $15.78 | 2023 | |
| Genentech USA, INC. | $14.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tommy Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.